Genzyme BioSurgery
This article was originally published in The Gray Sheet
Executive Summary
Enrollment is under way for two separate, six-center, 25-patient, placebo-controlled U.S. trials of the HIF-1alpha angiogenesis product for use as an adjunct to CABG surgery, and for peripheral vascular disease, respectively. "The Gray Sheet" (Feb. 19, 2001, p. 18) incorrectly reported the studies were being conducted in Europe. In addition, the firm intends to start clinical trials for its second generation Carticel product in Europe sometime this year. The current version delivers harvested cartilage cells through open-knee surgery and not arthroscopically. Planned improvements will not include elimination of the cell harvesting procedure